# Early Phase Clinical Research Support

> **NIH NIH P30** · UNIVERSITY OF MARYLAND BALTIMORE · 2020 · $140,179

## Abstract

14.0 Abstract: Early Phase Clinical Research Support 
UMGCC investigator-initiated pilot (pre-Phase I) or Phase I trials that test clinical interventions with a candidate 
agent or device for the diagnosis, prevention, detection, or treatment of cancer frequently require funding to 
support research coordination, data management, and regulatory functions. Data from these trial protocols can 
be used to support later-phase activities with these interventions or as a basis for acquiring funding from other 
sources to continue the piloted activities. This critical early support provided by Early Phase Clinical Research 
Support (EPCRS) is necessary to move such trials forward, especially because per-patient costs are not 
reimbursed. EPCRS funds will be for UMGCC personnel, including research coordinators and data managers, 
to facilitate innovative clinical investigation efforts. Trials supported by EPCRS will be subject to additional 
criteria for consideration by the Clinical Research Committee either before their implementation and 
development or after needs emerge that are not addressed by other sponsoring agencies. The trials will be 
assigned a priority scale for funding based on how the protocol is significant and innovative in promoting the 
development of novel cancer diagnosis, treatment, imaging, or prevention strategies and based on evidence 
that the trial will enable correlative science as a result of EPCRS funding, with translational collaborators and 
assays in place. During the most recent 5-year funding period, 21 trials were developed by UMGCC 
investigators within the guidelines for funding through EPCRS. The narrative highlights five protocols recently 
launched or in development as examples of trials that will benefit from EPCRS in the future. These trials flow 
from investigator-initiated clinical research or are the logical consequence of an alliance between basic 
scientists at UMGCC and clinicians well suited to address a translational science goal and are either not 
incorporated into other grant-supported or Cooperative Group trials of NCI or other funding agencies or have 
only partial industry support.

## Key facts

- **NIH application ID:** 9984998
- **Project number:** 5P30CA134274-13
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** Christian Diego Rolfo
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $140,179
- **Award type:** 5
- **Project period:** 2008-08-08 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9984998

## Citation

> US National Institutes of Health, RePORTER application 9984998, Early Phase Clinical Research Support (5P30CA134274-13). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9984998. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*